Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newman, R. P.
Right arrow Articles by Larsen, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newman, R. P.
Right arrow Articles by Larsen, T. A.
NEUROLOGY 1985;35:571
© 1985 American Academy of Neurology

Motor function in the norimal aging population

Treatment with levodopa

Richard P. Newman, MD, Peter A. LeWitt, MD, Miles Jaffe, MSOD, Donald B. Calne, DM and T. Andreo Larsen, MD

Experimental Theralpeutics Branch (Drs. Newman and LeWitt), National Institute of Neurological, Communicative Disorders and Stroke, and Section of Visual Processing (Dr. Jaffe), National Eye Institute, National Institutes of Health, Bethesda, MD; and the University of British Columbia, Health Sciences Centre Hospital (Drs. Calne and Larsen), Vancouver, BC.

In normal elderly humans there is progressive motor dysfunction and loss of nigrostriatal neurons and brain dopamine similar to, although of a milder degree than, that seen in Parkinson's disease. Ten healthy elderly volunteers were given carbidopafievodopa or placebo in a double-blind crossover study. We measured movement velocity, reaction time, tremor, visual evoked response (VER), and electroretinography (ERG). Significant changes were seen only in ERG. Motor functions and VER were unchanged. Although there appeared to be pharmacologic activity (ie, changes in ERG), levodopa, in adequate antiparkinson dosage, had no impact on the mild extrapyramidal impairment of normal elderly subjects.

Address correspondence and reprint requests to Dr. Newman, 1004 Beverly Dr., Rockledge, FL 32955.

Accepted for publication August 6, 1984




This article has been cited by other articles:


Home page
 Arch NeurolHome page
G. Levy, E. D. Louis, L. Cote, M. Perez, H. Mejia-Santana, H. Andrews, J. Harris, C. Waters, B. Ford, S. Frucht, et al.
Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease
Arch Neurol, March 1, 2005; 62(3): 467 - 472.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. Russmann, J. Ghika, J.-G. Villemure, B. Robert, J. Bogousslavsky, P. R. Burkhard, and F. J.G. Vingerhoets
Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years
Neurology, November 23, 2004; 63(10): 1952 - 1954.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
N. Kubis, B. A. Faucheux, G. Ransmayr, P. Damier, C. Duyckaerts, D. Henin, B. Forette, Y. Le Charpentier, J.-J. Hauw, Y. Agid, et al.
Preservation of midbrain catecholaminergic neurons in very old human subjects
Brain, February 1, 2000; 123(2): 366 - 373.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. A. Bennett, L. A. Beckett, A. M. Murray, K. M. Shannon, C. G. Goetz, D. M. Pilgrim, and D. A. Evans
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
N. Engl. J. Med., January 11, 1996; 334(2): 71 - 76.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.